5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Kapp, Friedrich G ^a,b   Sommer, Anette ^a   Kiefer, Thomas ^b   Dölken, Gottfried ^b   Haendler, Bernard ^a  

^a Global Drug Discovery   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; SMALL INTERFERING RNA; STEROID 5ALPHA REDUCTASE 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84855903912     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-1     Document Type: Article

References (35)

1. RKI Krebs in Deutschland 2005/2006-Häufigkeiten und Trends. , http://www.rki.de/nn_1869836/DE/Content/GBE/DachdokKrebs/KID/kid__node.html?__nnn=true
2. Smythe WR. Treatment of stage I non-small cell lung carcinoma. Chest 2003, 123:181S-187S. 10.1378/chest.123.1_suppl.181S, 12527578.
3. Scott WJ, Howington J, Movsas B. Treatment of stage II non-small cell lung cancer. Chest 2003, 123:188S-201S. 10.1378/chest.123.1_suppl.188S, 12527579.
4. Müller-Hagen G, Beinert T, Sommer A. Aspects of lung cancer gene expression profiling. Curr Opin Drug Discov Devel 2004, 7:290-303.
5. Langer W, Sohler F, Leder G, Beckmann G, Seidel H, Grone J, Hummel M, Sommer A. Exon Array Analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer. BMC Genomics 2010, 11:676. 10.1186/1471-2164-11-676, 3053589, 21118496.
6. Schmidt LJ, Tindall DJ. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. J Steroid Biochem Mol Biol 2011, 125:32-38. 10.1016/j.jsbmb.2010.09.003, 20883781.
7. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008, 99:81-86.
8. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, De Brouwer AP, Blümel P, Sykut-Cegielska J, Houliston S, Swistun D, Ali BR, Dobyns WB, Babovic-Vuksanovic D, van Bokhoven H, Wevers RA, Raetz CRH, Freeze HH, Morava E, Al-Gazali L, Gleeson JG. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 2010, 142:203-217. 10.1016/j.cell.2010.06.001, 2940322, 20637498.
9. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993, 92:903-910. 10.1172/JCI116665, 294929, 7688765.
10. Jakimiuk AJ, Weitsman SR, Magoffin DA. 5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1999, 84:2414-2418. 10.1210/jc.84.7.2414, 10404813.
11. Provost PR, Blomquist CH, Godin C, Huang XF, Flamand N, Luu-The V, Nadeau D, Tremblay Y. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3. Endocrinology 2000, 141:2786-2794. 10.1210/en.141.8.2786, 10919264.
12. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW, Su AI. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 2009, 10:R130. 10.1186/gb-2009-10-11-r130, 3091323, 19919682.
13. Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004, 4:27-27. 10.1186/1471-2407-4-27, 459223, 15212687.
14. Das K, Lorena PDN, Ng LK, Lim D, Shen L, Siow WY, Teh M, Reichardt JKV, Salto-Tellez M. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer 2010, 17:757-770. 10.1677/ERC-10-0022, 20519274.
15. Egner U, Krätzschmar J, Kreft B, Pohlenz H-D, Schneider M. The target discovery process. Chembiochem 2005, 6:468-479. 10.1002/cbic.200400158, 15742383.
16. Applied Biosystems Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR 2008, Applied Biosystems.
17. Yuan JS, Reed A, Chen F, Stewart CN. Statistical analysis of real-time PCR data. BMC Bioinformatics 2006, 7:85. 10.1186/1471-2105-7-85, 1395339, 16504059.
18. Quantifying western blots without expensive commercial quantification software. , http://www.lukemiller.org/journal/2007/08/quantifying-western-blots-without.html
19. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alpha-reductase inhibitors. Steroids 2010, 75:109-153. 10.1016/j.steroids.2009.10.005, 19879888.
20. Menzenbach B, Droescher P, Hillisch A, Elger W, Schweikert H, Schöllkopf K. Methylene-4-azasteroids (WO 2003020744) 2003,
21. Klar U, Hoffmann J, Giurescu M. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate. Expert Opin Investig Drugs 2008, 17:1735-1748. 10.1517/13543784.17.11.1735, 18922109.
22. Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res 2010, 16:1452-1465. 10.1158/1078-0432.CCR-09-2455, 20179216.
23. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994, 63:25-61. 10.1146/annurev.bi.63.070194.000325, 7979239.
24. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 2003, 100:6347-52. 10.1073/pnas.1131959100, 164449, 12746500.
25. Chatterjee-Kishore M, Miller CP. Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation. Drug Discov Today 2005, 10:1559-65. 10.1016/S1359-6446(05)03623-8, 16257379.
26. Santos ES, Perez CA, Raez LE. How is gene-expression profiling going to challenge the future management of lung cancer?. Future Oncol 2009, 5:827-835. 10.2217/fon.09.60, 19663732.
27. Zhu C-Q, Pintilie M, John T, Strumpf D, Shepherd FA, Der SD, Jurisica I, Tsao M-S. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer 2009, 10:331-340. 10.3816/CLC.2009.n.045, 19808191.
28. Agulló-Ortuño MT, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol 2010, 5:1673-1691. 10.1097/JTO.0b013e3181f1900e, 20736853.
29. Alvarez-Salas LM. Nucleic acids as therapeutic agents. Curr Top Med Chem 2008, 8:1379-1404. 10.2174/156802608786141133, 18991725.
30. Sioud M. Promises and challenges in developing RNAi as a research tool and therapy. Methods Mol Biol 2011, 703:173-187. 10.1007/978-1-59745-248-9_12, 21125490.
31. Huppi K, Martin SE, Caplen NJ. Defining and assaying RNAi in mammalian cells. Mol Cell 2005, 17:1-10.
32. Elliott NT, Yuan F. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 2011, 100:59-74. 10.1002/jps.22257, 20533556.
33. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010, 148:3-15. 10.1016/j.jbiotec.2010.01.012, 20097238.
34. Shekhar MPV. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets 2011, 11:613-623.
35. Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund L-T. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011, 6:209-217. 10.1097/JTO.0b013e3181f8a1bd, 21107292.